文献速递类风湿关节炎

超低剂量利妥昔单抗维持治疗类风湿关节炎的随机对照非劣效性试验(REDO研究)

Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial.
PubMed 文献 · Lancet Rheumatol · 2019-10-23

REDO研究为在荷兰五中心开展的随机双盲非劣效性试验,纳入了对利妥昔单抗应答良好的成人类风湿关节炎患者142例,按1:2:2随机接受每6个月一次静脉利妥昔单抗1000mg、500mg或200mg。结果显示500mg剂量在3个月时非劣效于1000mg,但在6个月时未达到非劣效;因分层检验程序,200mg剂量未能进行非劣效检验。超低剂量组感染发生率显著低于标准剂量组。

要点

  • 500mg利妥昔单抗在3个月时非劣效于1000mg,但6个月时未达到非劣效。
  • 因分层检验程序,200mg剂量未能进行非劣效检验。
  • 超低剂量组感染发生率显著低于1000mg组。

核心结论

  • 本研究未显示超低剂量利妥昔单抗用于类风湿关节炎继续治疗的非劣效性。
  • 在临床实践中,评估风险与获益后可考虑超低剂量利妥昔单抗策略,但需进一步研究确立非劣效性。

研究设计与样本

  • REDO研究为随机、双盲、非劣效性试验,在荷兰五个中心开展。
  • 纳入年龄≥18岁、对利妥昔单抗应答良好的类风湿关节炎患者,随机(1:2:2)分配至静脉利妥昔单抗1000mg、500mg或200mg组。
  • 随机化列表由计算机生成,按类风湿因子或抗环瓜氨酸蛋白抗体状态及是否联用传统合成改善病情抗风湿药分层。

主要发现

  • 因分层检验程序,200mg剂量未能进行非劣效检验。
  • 13例患者发生严重不良事件,1000mg组3例(10%)、500mg组6例(10%)、200mg组4例(7%);最常见严重不良事件为心血管事件;研究期间无死亡。

临床怎么用

  • 对利妥昔单抗应答良好的类风湿关节炎患者,在评估风险与获益后可考虑超低剂量(500mg或200mg)维持治疗,但需注意6个月时500mg未达非劣效。
  • 超低剂量利妥昔单抗可能降低感染风险,但需进一步研究确立非劣效性。

局限性

  • 因分层检验程序,200mg剂量未能进行非劣效检验。
  • 研究未显示超低剂量非劣效,需进一步分析和2年观察性延伸研究提供更多证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rituximab is an effective treatment for rheumatoid arthritis, given as either two doses of 1000 mg (2 weeks apart) every 6 months (the dose recommended by the US Food and Drug Administration and European Medicines Agency) or two doses of 500 mg (2 weeks apart) or one dose of 1000 mg (a standard low dose) every 6 months. Findings of several small uncontrolled studies suggest that doses lower than the recommended dose or standard low dose might be sufficient for maintenance treatment, potentially improving safety and reducing costs. Therefore, we aimed to compare the efficacy of ultra-low doses of rituximab (one dose of 500 mg or 200 mg) with a standard low dose of rituximab (one dose of 1000 mg) for patients with rheumatoid arthritis who respond to standard doses of rituximab. METHODS: The REDO study is a randomised, double-blind, non-inferiority trial done at five centres in the Netherlands. Adults (aged ≥18 years) with rheumatoid arthritis responding well to rituximab were randomly allocated (1:2:2) to receive intravenous rituximab as one dose of either 1000 mg, 500 mg, or 200 mg, respectively. Volumes of all doses were equal to achieve masking. Randomisation lists were computer-generated and stratified by rheumatoid factor or anti-citrullinated protein antibody status (positive or negative) and concomitant use of conventional synthetic disease modifying antirheumatic drugs (yes or no). The primary analysis was a per-protocol hierarchical testing procedure comparing ultra-low doses with a standard low dose (500 mg vs 1000 mg at 3 months, followed by 500 mg vs 1000 mg at 6 months, 200 mg vs 1000 mg at 3 months, and 200 mg vs 1000 mg at 6 months), using a non-inferiority margin of 0·60 on change from baseline in the 28-joint disease activity score based on C-reactive protein levels (DAS28-CRP). The study is registered at www.trialregister.nl, NTR6117. FINDINGS: Between Dec 15, 2016, and Sept 20, 2018, 142 patients were randomly allocated to either 1000 mg rituximab (n=29), 500 mg rituximab (n=58), or 200 mg rituximab (n=55). The 500 mg dose was non-inferior to 1000 mg at 3 months (mean change from baseline in DAS28-CRP, -0·07, 95% CI -0·41 to 0·27) but not at 6 months (0·29, -0·08 to 0·65). Because of the hierarchical testing procedure, non-inferiority could not be tested for the 200 mg dose. 13 patients had serious adverse events, three (10%) in the 1000 mg group, six (10%) in the 500 mg group, and four (7%) in the 200 mg group. The most frequently reported serious adverse events were cardiovascular. No deaths occurred during the study. A significantly lower incidence of infections was seen in the ultra-low-dose groups compared with the standard dose group (1·10 infections per patient-year with the 1000 mg dose vs 0·52 per patient-year with the 500 mg dose and 0·51 per patient-year with the 200 mg dose; rate ratio 0·47, 95% CI 0·21-0·83; p=0·013 for 500 mg vs 1000 mg; 0·44, 0·22-0·88; p=0·019 for 200 mg vs 1000 mg). INTERPRETATION: Our study did not show non-inferiority of ultra-low doses of rituximab for continued treatment of patients with rheumatoid arthritis. Nonetheless, in clinical practice, a strategy with an ultra-low dose of rituximab might be considered after evaluation of risks and benefits, although further studies are needed to establish non-inferiority. Further analyses and a 2-year observational extension are ongoing and should provide further insight into efficacy and safety. FUNDING: Menzis and Centraal Ziekenfonds.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Verhoef LM, den Broeder N, Thurlings RM, et al. Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial. Lancet Rheumatol. 2019. PMID: 38229391. doi:10.1016/S2665-9913(19)30066-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。